<span item_type="fundamental" item_id="df900f723874fa95ea53f1c54413e5bc" counter_id="ST/US/BFRI" env="prod"></span><span item_type="announcement" item_id="648251836518040449" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 10.08 M, missing the estimate of USD 10.25 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.41, missing the estimate of USD -0.115.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -4.627 M.</p><p></p><h3>First Quarter 2026 Financial Highlights</h3><h4>Revenue</h4><p>Total revenues for the first quarter of 2026 were $10.1 million, marking approximately a 17% increase compared to $8.6 million for the same period in 2025. This growth was primarily driven by approximately 16% growth in the number of Ameluz units sold and a price increase implemented in the fourth quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p><h4>Gross Margins</h4><p>Gross margins were approximately 80% in Q1 2026, an 18 percentage points increase compared to approximately 62% in Q1 2025. This reflects the first full quarter under the new earnout structure following the Strategic Transaction in October 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span> Cost of revenues, related party, decreased by approximately 40% year over year, due to the transition to the lower earnout structure.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span> Biofrontera Inc. recognized $1.2 million in earnout expense during Q1 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p><h4>Operating Profit / Loss</h4><p>Operating loss was - $4.3 million in Q1 2026 compared to a loss of - $4.5 million in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p><h4>Operating Expenses</h4><p>Total operating expenses were $14.4 million for the first quarter of 2026, up from $13.1 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span> Selling, general and administrative expenses were $11.0 million in Q1 2026, compared to $8.7 million in Q1 2025, primarily due to higher selling and marketing costs, increased legal expenses, and manufacturing-related costs assumed from the Strategic Transaction.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span> Research and development expenses were $0.9 million for Q1 2026, a decrease from $1.2 million in Q1 2025, mainly due to certain clinical trials reaching substantial completion.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p><h4>Net Loss</h4><p>The net loss for the first quarter of 2026 was - $4.8 million, compared with a net loss of - $4.2 million for the prior-year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p><h4>Adjusted EBITDA (Non-GAAP)</h4><p>Adjusted EBITDA improved to - $3.6 million in Q1 2026 from - $4.4 million in Q1 2025, an improvement of approximately $0.8 million, reflecting expanded gross margins.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span> Adjusted EBITDA margin improved to -35.3% from -51.0% in the prior-year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p><h4>Cash Flow</h4><p>Cash flows used in operating activities were - $70 thousand in Q1 2026, a significant improvement from - $4,117 thousand used in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span> Cash, cash equivalents and restricted cash, at the end of Q1 2026, was $6,517 thousand, compared to $1,985 thousand at the end of Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p><h3>Outlook</h3><p>Biofrontera Inc. aims to achieve sustained profitability and cash-flow breakeven while building a foundation for medium to long-term growth.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span> The company anticipates multiple near-term catalysts from its clinical pipeline, including a PDUFA date for sBCC in September 2026, positive Phase 3 results for AK on the neck/trunk and extremities, and encouraging Phase 2b data in acne.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span> These advancements are expected to meaningfully expand the commercial opportunities for the Ameluz platform.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p>

Biofrontera | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 10.08 M